Skip to main content
Clinical Trials/JPRN-UMIN000011666
JPRN-UMIN000011666
Recruiting
未知

Peginterferon or conventional interferon sequential entecavir treatment for hepatitis B e antigen positive chronic hepatitis B patients: a prospective randomized controlled trial - Peginterferon or conventional interferon sequential entecavir treatment

Toranomon Hospital0 sites100 target enrollmentSeptember 9, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
chronic hepatitis B
Sponsor
Toranomon Hospital
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Prior exposure of interferon, antiviral agents, antitumoral agents, immunosupressive drugs, and radiotherapy within 6 months 2\. HCV RNA positivity 3\. Complicating other liver disease 4\. The diagnosis of Liver cirrhosis, hepatic failure, and liver cancer 5\. The history of hepatic encephalopathy, varices bleeding, and ascites 6\. Complicating collagen disease 7\. The history of interstitial pneumonia 8\. Severe heart disease 9\. The history of epilepsy 10\. The history of depression 11\. The history of abnormal thyroid function 12\. The history of stroke 13\. Severe diabetes 14\. The history of malignant tumor within 5 years 15\. The history of liver, kidney or bone marrow transplantation 16\. Retinopathy 17\. blood test abnormality as follows: (a) neutrophil \< 1,500 /mm3 (b) platelets count \< 90,000/ mm3 (c) Hb \< 10 g/dL (d) prothrombin time \> 20s or \< 60% (e) ALT \> 10 times ULN (f) total bilirubin \> 2\.0 mg/dL (g) albmin \< 3\.2 g/dL (h) creatinine clearance \< 50 mL/min 18\. Pregnancy 19\. Doctors condider inadequate

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4Hepatitis C virus (HCV)Infections and InfestationsChronic viral hepatitis
ISRCTN59358441Academic Medical Centre (AMC) (Netherlands)58
Completed
Not Applicable
Interferon induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.chronic hepatitis C
NL-OMON27278AMC Liver Center, Department GastroAcademic Medical Center, University of Amsterdam58
Completed
Phase 3
The effect of Combination Peg interferon –alpha to Tenofovir versus each one of the treatment modalities alone on Patients with HBeAg-negative: A randomized clinical trial
IRCT20181113041635N1vice presidency for siences and technology , Iran national silences foundation60
Active, not recruiting
Not Applicable
Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 µg/l - KAPRI
EUCTR2006-000504-17-DEHeinrich-Heine-Universität Düsseldorf
Active, not recruiting
Not Applicable
COMBINED THERAPY WITH PEG-INTERFERON-a, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA - NDpatients anti-HCV, HCV RNA positivity, Na?ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitisMedDRA version: 9.1Level: SOCClassification code 10005329
EUCTR2010-020659-30-ITAZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE